

1 **Deciphering Risk of Recurrent Bone Stress Injury in Female Runners Using**  
2 **Serum Proteomics Analysis and Predictive Models**

3 **Authors:** Genevieve E. Romanowicz<sup>1</sup>, Kristin Popp<sup>2,3,4</sup>, Ethan Dinh<sup>1</sup>, Isabella R. Harker<sup>1</sup>, Kelly  
4 Leguineche<sup>1</sup>, Julie M. Hughes<sup>5</sup>, Kathryn E. Ackerman<sup>2,3</sup>, Mary L. Bouxsein<sup>2,6</sup>, Robert E.  
5 Guldberg<sup>1</sup>

6 **Affiliations:**

7  
8 <sup>1</sup>Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR

9 <sup>2</sup>Endocrine Division, Massachusetts General Hospital, Boston, MA

10 <sup>3</sup>Boston Children's Hospital, Boston, MA

11 <sup>4</sup>TRIA Orthopedics, HealthPartners Institute, Bloomington, MN

12 <sup>5</sup>Military Performance Division, United States Army Research Institute of Environmental  
13 Medicine, Natick, Massachusetts, USA

14 <sup>6</sup>Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center, Boston, MA

15 \*Corresponding author. Email: [guldberg@uoregon.edu](mailto:guldberg@uoregon.edu)

16 **Abstract:**

17 Up to 40% of elite athletes experience bone stress injuries (BSIs), with 20-30% facing reinjury.  
18 Early identification of runners at high risk of subsequent BSI could improve prevention strategies.  
19 However, the complex etiology and multifactorial risk factors of BSIs makes identifying predictive  
20 risk factors challenging. In a study of 30 female recreational athletes with tibial BSIs, 10  
21 experienced additional BSIs over a 1-year period, prompting investigation of systemic biomarkers  
22 of subsequent BSIs using aptamer-based proteomic technology. We hypothesized that early  
23 proteomic signatures could discriminate runners who experienced subsequent BSIs. 1,500 proteins  
24 related to metabolic, immune, and bone healing pathways were examined. Using supervised  
25 machine learning and genetic programming methods, we analyzed serum protein signatures over  
26 the 1-year monitoring period. Models were also created with clinical metrics, including standard-  
27 of-care blood analysis, bone density measures, and health histories. Protein signatures collected  
28 within three weeks of BSI diagnosis achieved the greatest separation by sparse partial least squares  
29 discriminant analysis (sPLS-DA), clustering single and recurrent BSI individuals with a mean  
30 accuracy of  $96 \pm 0.02\%$ . Genetic programming models independently verified the presence of  
31 candidate biomarkers, including fumarylacetoacetase, osteopontin, and trypsin-2, which  
32 significantly outperformed clinical metrics. Time-course differential expression analysis  
33 highlighted 112 differentially expressed proteins in individuals with additional BSIs. Gene set  
34 enrichment analysis mapped these proteins to pathways indicating increased fibrin clot formation  
35 and decreased immune signaling in recurrent BSI individuals. These findings provide new insights  
36 into biomarkers and dysregulated protein pathways associated with recurrent BSI and may lead to  
37 new preventative or therapeutic intervention strategies.

38 **One Sentence Summary:** Our study identified candidate serum biomarkers to predict subsequent  
39 bone stress injuries in female runners, offering new insights for clinical monitoring and  
40 interventions.

41

42

43 **Main Text:**

44 **INTRODUCTION**

45 Bone stress injuries (BSIs) are common in active individuals, affecting professional and  
46 amateur athletes (1 in 20 individuals) (1, 2) and military personnel undergoing initial military  
47 training (as high as 1 in 10 individuals) (1, 3, 4). For athletes, BSIs are one of the most burdensome  
48 injuries, with 20-40% of athletes experiencing BSIs during training (5, 6). While BSIs can range  
49 in severity, they may have an outsized financial and psychological impact due to high rates of  
50 additional BSIs and extended absences from sport (7). Methods to improve BSI healing, enhance  
51 early detection, and inform preventative strategies would remove an obstacle to training and  
52 improve athlete well-being. Yet the etiology and pathogenesis of BSIs are multifactorial and  
53 complex, making identification of a single factor leading to subsequent BSIs (new BSI at the same  
54 or different location) and ultimately the prevention of new BSIs challenging.

55 A history of a prior BSI is one of the strongest risk factors for a recurrent BSI (2, 6).  
56 Diagnosis of these injuries is accomplished through magnetic resonance imaging (MRI), x-ray  
57 based imaging, or clinical symptoms. The standard of care for return to play is based off absence  
58 of pain with progressive physical activity after an initial period of rest/unloading. For high-risk  
59 BSIs, repeat MRI may also be ordered to ensure healing. However, current biomarkers (8), clinical  
60 assessments [MRI, dual-energy x-ray absorptiometry (DXA), and computed tomography (CT)] (9)  
61 lack reliable sensitivity and specificity in identifying individuals at risk of subsequent BSIs. Return  
62 to sport is highly individualized based on the patient specific risk factors and pain levels with  
63 loading (10). Together, variability in diagnostics, prognostics, risk factors, and treatment regimens  
64 has made the identification of individuals at risk of subsequent BSIs challenging.

65 Although most runners with BSIs are able to return to activity after rest, the frequency of  
66 subsequent BSIs ranges from 20-30% (11, 12). Recurrence of BSIs at the same or different  
67 locations, are ~3 times greater in women compared to men (5). Recovery from a BSI can range  
68 from 4 weeks to 6 months (9, 12, 13), causing extended removal from sport. While thus far elusive,  
69 identification of a reliable biomarker or biomarker panel, would dramatically improve clinical  
70 decision making for return to activity and post-injury management as well as prevention and  
71 treatment of BSIs.

72 In our previously reported study, female recreational runners who experienced a  
73 subsequent BSI were younger, more likely to have a history of prior skeletal fracture, and had later  
74 onset of menses and lower serum parathyroid hormone (PTH) levels than female athletes who did  
75 not experience a subsequent BSI (11). Notably, bone density and microarchitecture was largely  
76 similar between athletes who did and did not suffer a recurrent BSI, though women who had a  
77 reinjury had lower cortical bone tissue mineral density (TMD) and estimated stiffness at the distal  
78 tibia (11). Altogether, there was no set of clinical or performance-related factors that distinguished  
79 between individuals who would sustain a subsequent BSI during the one year follow up and those  
80 who would heal uneventfully. This informed our current study with the objective to identify protein  
81 signatures in individuals who experience subsequent BSIs to address these clinical challenges.

82 The identification of biomarkers in bone healing is an emerging field, supported by the  
83 development of sophisticated machine learning (ML) models designed to navigate the  
84 complexities of high-dimensional datasets characterized by limited sample sizes, multi-omic  
85 integration, and biological noise (14). Genetic programming-based ML approaches have proven  
86 effective in extracting critical insights from such datasets. Additionally, high-throughput

87 proteomic technologies, such as the SOMAscan assay (15–17), enable simultaneous quantification  
88 of over 1,500 proteins from human serum with exceptional precision, enhancing the detection of  
89 biological signals. However, these advancements also amplify the challenge of “small n” datasets,  
90 where the number of variables vastly exceeds the sample size, increasing the risk of overfitting  
91 (18). Despite this, when strong signals exist, it is possible to identify highly informative feature  
92 sets which are predictive in the clinical context.

93 Our study leverages established machine learning and genetic programming models to  
94 interrogate both linear and non-linear relationships within high-resolution proteomic data. By  
95 combining advanced proteomic profiling with ML, we provide critical insights into diagnostics,  
96 early intervention, and personalized risk assessment in sports medicine. Furthermore, our dataset  
97 represents the most comprehensive serum proteomic analysis for BSI studies to date, illuminating  
98 dysregulated biological pathways in an underexplored population of female athletes.


## 99 RESULTS

### 100 Study Cohort

101 Utilizing samples serum from our previous study (11), we sought to characterize the  
102 proteomic signatures of individuals with and without additional BSI's over a one-year recovery  
103 period. The original study enrolled female recreational athletes (n=30) (Fig. 1) from the local  
104 community who were diagnosed with a tibial BSI with MRI Grading of 2-4/4 by Fredericson  
105 Criteria (11). Patients were enrolled within 3 weeks of initial BSI MRI diagnosis. At enrollment,  
106 areal bone mineral density (aBMD) of the hip and spine were assessed by DXA, while volumetric  
107 bone mineral density (vBMD) and bone microarchitecture at the distal tibia were measured via  
108 high-resolution peripheral quantitative computed tomography (HR-pQCT). HR-pQCT scans were  
109 also collected at each follow up visit, including 6, 12, 24, and 52 weeks after the initial enrollment.  
110 Additionally, clinical metrics were collected, including laboratory blood values, pain assessments,  
111 physical activity assessments, menstrual status, and health and fracture history (full list in Data  
112 File S1, data previously reported (11)). Of the 30-runner cohort, 10 experienced additional BSIs  
113 at times ranging from 6-52 weeks after initial diagnosis (11). The majority occurred between weeks  
114 12 and 52 (9 out of 10 additional BSIs) (Table 1). One individual had a third BSI event in the 24-  
115 to-52-week period. Only one additional BSI was in the same location as the first BSI. For all  
116 individuals, serum was analyzed retrospectively for protein signatures of additional BSI (full list  
117 in Data file S2).

118 **Table 1. Summary of additional BSI events during the 52 weeks of monitoring.** A total  
119 of 10 of 30 participants experienced a 2<sup>nd</sup> BSI, with one individual experiencing a 3<sup>rd</sup> BSI.  
120 Only one BSI was at the same location as the original BSI. Data previously reported in  
121 *Popp, et al., 2019.*

Time Window	2 <sup>nd</sup> BSI	3 <sup>rd</sup> BSI
Enrollment - 6 weeks	1	
6 - 12 weeks	0	
12-24 weeks	5	
24-52 weeks	4	1
<b>Total:</b>	10 Additional BSIs	



122

123 **Figure 1: Study design and patient attrition.** (A) Female recreational athletes were  
 124 recruited to participate in an observational study following bone stress injury (BSI) diagnosis  
 125 with an MRI Fredericson grade 2-4/4. Patient attrition and visit completion are noted. *Figure*  
 126 *adapted from Popp, et al. 2019.* (B) All patients were enrolled within 3 weeks of diagnosis  
 127 of a tibial BSI and monitored for metrics such as bone morphometry changes, physical  
 128 activity, and pain. Serum was collected and originally analyzed for standard of care  
 129 laboratory values. This study re-analyzed the serum for 1,500 proteins across all individuals  
 130 and times. Of the 30 individuals, 20 went on to recover without additional injury. 10  
 131 individuals experienced a second BSI, with one individual experiencing a third BSI over the  
 132 one year follow up (Table 1). Created in <https://BioRender.com>

133

134

135 **Additional and single BSI groups can be identified based on early protein signatures at time**  
136 **of enrollment and before any additional BSI events.**


137 The sparse partial least squares discriminant analysis sPLS-DA model was chosen to  
138 identify key features from the enrollment visit (visit 1, < 3 weeks after initial BSI diagnosis),  
139 separating additional BSI individuals from single BSI individuals. Models were first applied to the  
140 clinical outcomes (11). Separation was not clear for the clinical data, with the top-ten features  
141 identified as age at menses onset, cortical TMD (Ct. TMD), compressive stiffness (Comp. Stiff.),  
142 age, failure load (F. Load), and prior number of fractures (Prior FX) (Fig. 2A&D), all of which  
143 were previously reported (11) to be different between additional and single BSI groups. Serum  
144 procollagen type I N-propeptide (P1NP) and serum osteocalcin were also included in the top-ten  
145 features (Fig. 2D, Data File S3). These serum metrics were measured using standard-of-care  
146 clinical laboratory assays in the previous study (11), and are different than the aptamer based serum  
147 proteomic data. Due to the small sample size, feature importance estimation via bootstrapping was  
148 conducted on the sPLS-DA models. The bootstrapping method included repeated removal of one  
149 participant and recording of the top model features. Stable features, identified as those appearing  
150 in at least 80% of models following bootstrapping (Data File S4), were then evaluated for  
151 predictive performance via Receiver Operating Characteristic (ROC) analysis. Due to the small  
152 sample size and class imbalance in the data, leave one out cross validation (LOOCV) was applied.  
153 For the clinical data, the features selected were medical history (age, age at menses onset, prior  
154 history of fracture), tibia morphology via HR-pQCT (CtTMD, stiffness and strength), and serum  
155 markers of bone metabolism (P1NP, tartrate-resistant acid phosphatase 5b (TRAP5b)). The area  
156 under the curve (AUC) for mean ROC curve indicated an average accuracy of  $79\% \pm 0.08$  across  
157 various predictive models including Logistic Regression, Random Forest, and CatBoost (Fig. 2G).  
158 The average sensitivity was 63.3% and average specificity was 76.7% (Fig. S1A). The positive  
159 predictive value was 57.6% and negative predictive value was 80.7% (Fig. S1A).

160 Similar models were generated for the serum proteomic data. sPLS-DA was performed on  
161 serum proteomic data from the enrollment visit. Ten proteins were identified which segregated the  
162 single vs. additional BSI groups (Fig. 2B). Of these, fumarylacetoacetase (FAAA), trypsin-2, and  
163 adiponectin were identified with the highest coefficients and greatest influence on the models to  
164 discriminate between single and additional BSIs (Fig. 2E). Less influential, but still important  
165 features included soluble vascular endothelial growth factor receptor 2 (VEGF sR2), tumor  
166 necrosis factor (TNF) receptor superfamily member 1B (TNF sR-II), osteopontin (OPN), telomeric  
167 repeat binding factor 1 (TERF1), Hsp70-binding protein 1 (HPBPI), Bcl2-associated agonist of  
168 cell death (BAD), and Interferon-induced helicase C domain-containing protein 1 (IFIH1) (Data  
169 File S3). Features present in at least 80% of models were FAAA, trypsin-2, adiponectin, OPN,  
170 TNF sR-II, VEGF sR2 (Data File S4). These proteins were then evaluated with an ROC analysis  
171 and LOOCV. The AUC for the mean ROC curve indicated an average accuracy of  $96\% \pm 0.02$   
172 across various predictive models including Logistic Regression, Random Forest, and CatBoost  
173 (Fig. 2H). The average sensitivity was 80.0% and average specificity was 98.3% (Fig. S1B). The  
174 positive predictive value was 96.0% and negative predictive value was 90.8% (Fig. S1B). The  
175 proteomic data models performed better (mean AUC  $\pm$  S.E.) than clinical data ( $p = 0.012$ , one-  
176 way ANOVA).

177 To determine if combining datasets would improve accuracy of the models, we then  
178 repeated the sPLS-DA models with both the clinical and the proteomic datasets. Combined  
179 datasets slightly increased separation between the two patient populations (Fig. 2C). Yet, of the

180 top-10 variables, only one clinical metric (age at onset of menses) was included (Fig. 2F, Data File  
181 S3). Features present in at least 80% of models included FAAA, trypsin 2, age at menses onset,  
182 adiponectin, TNF sR-II, and OPN (Data File S4). These six features were then evaluated with a  
183 ROC analysis and LOOCV. The AUC for the mean ROC curve indicated an average accuracy of  
184  $95\% \pm 0.02$  across various predictive models including Logistic Regression, Random Forest, and  
185 CatBoost (Fig. 2I). The average sensitivity was 80.0% and average specificity was 93.3% (Fig.  
186 S1C). The positive predictive value was 85.7% and the negative predictive value was 90.3% (Fig.  
187 S1C). While the average accuracy was similar between the proteomic data model and the combined  
188 data model, the combined models had a small reduction in sensitivity with increased specificity.  
189 The combined models performed better (mean AUC  $\pm$  S.E.) than clinical data ( $p = 0.017$ , one-way  
190 ANOVA), but not better than proteomic data ( $p = 0.97$ , one-way ANOVA).

191



192 **Figure 2: Bone stress injury (BSI) reinjury classification can be identified from**  
 193 **proteomic data within 3 weeks of initial BSI.** (A) Clinical data were used to separate  
 194 additional from single BSI individuals with a sparse partial least squares discriminant  
 195 analysis (sPLS-DA) model but yielded no clear separation. (B) Proteomic signatures were  
 196 then tested in a similar model, increasing separation. (C) Combining both clinical and  
 197 proteomic data marginally improves separation. (D) The top latent variables for the sPLS-  
 198 DA model are shown for clinical data, (E) proteomic data, and (F) the combined clinical  
 199 and proteomic data. (G) The most frequent variables identified by feature importance  
 200 estimation via bootstrapping were input into the sPLS-DA models and tested in predictive  
 201 models, including Logistic Regression, Random Forest, and CatBoost, each with leave  
 202 one out cross validation (LOOCV). Receiver operating characteristic (ROC) curves are  
 203 shown with a mean accuracy of 79% ± 0.08 for clinical data, (H) 96% ± 0.02 for proteomic  
 204 data, and (I) 95% ± 0.02 for the combined data. Shaded regions (A-C) represent the 95%  
 205 confidence interval. AUC values are mean ± S.E.



206 **Genetic programming models further support identification of candidate biomarkers of**  
207 **subsequent BSIs.**


208 Genetic programming has become a useful tool to generate predictive models in biological  
209 datasets where both linear and non-linear relationships may occur simultaneously (19, 20). We  
210 thus explored if linear and non-linear models would improve the predictive accuracy of both the  
211 proteomic and clinical datasets using Evolved Analytics DataModeler software. Thousands of  
212 models are generated across at least 30 successive generations, in which “fit” models are  
213 selectively bred. Finally, models are rated based on accuracy and complexity, and those with  
214 optimal complexity/accuracy tradeoffs are aggregated into a model ensemble. Complexity refers  
215 to a measure of numerical operations required to fit the data into either the additional or single BSI  
216 group. Lower complexity is desirable, with a complexity score > 80 considered too complex for  
217 our dataset based on sample size. Therefore, we sought to evaluate the complexity and accuracy  
218 of produced models for each of our datasets. Resultant model ensembles were used to predict a  
219 binary outcome measure: single vs. additional BSI. This approach allowed for an independent  
220 statistical validation of candidate biomarkers by utilizing a completely independent machine  
221 learning approach as compared to the linear models used in sPLS-DA. An additional advantage of  
222 genetic programming is that candidate equations that are used to generate the model ensembles are  
223 displayed as an output, showing the algorithmic relationship between features and enhancing  
224 interpretability.

225 Datasets were compared for accuracy and error including ‘Clinical Data’, ‘Proteomic Data’,  
226 or ‘Combined Data’ with the same datasets tested in the sPLS-DA models. Ten candidate models  
227 were selected from the thousands of models generated per category. Candidate models were  
228 restricted to 4 variables, which is the recommended number of variables to allow for at least a 5:1  
229 ratio of datapoints (individuals) to support selected variables (Fig. 3A-C). The first step in  
230 evaluating genetic programming model ensembles (collections of models) is to inspect if model  
231 ensembles exhibit a ‘knee’ shaped Pareto plot, which signifies a balance between minimizing error  
232 and avoiding unnecessary complexity. Minimizing error with balance complexity is a desirable  
233 trait in all models but is especially important with small datasets. The ‘knee’ shape was notably  
234 absent in models relying solely on clinical data (Fig. 3A) suggesting that accuracy could not be  
235 achieved without undue complexity and therefore risk of overfitting. Additionally, accuracy in this  
236 context signifies confidence in a binary classification (e.g., single or additional BSI), rather than  
237 estimate of a continuous variable.

238 Genetic programming models for the clinical metrics had the poorest performance, with  
239 resultant 10-model ensemble (Table S1) yielding relatively low accuracy ( $R^2 = 78\%$ ) and high  
240 error rates for single BSI predictions ( $17 \pm 14\%$ ) and for additional BSI predictions ( $29 \pm 13\%$ )  
241 across the selected 10 best performing models (Fig. 3D&E). Substantial variability between model  
242 ensembles was also present in clinical metrics alone (Fig. 3D). For the clinical models, the top-5  
243 most frequently occurring variables across the model ensemble included tibial length (40%),  
244 absolute lymphocyte count (40%), age at menses onset (40%), serum levels of 25 (OH) vitamin D  
245 (30%), and posteroanterior lumbar spine bone mineral content (PA-BMC) by DXA (30%).  
246 Furthermore, no variable was present in more than 50% of the selected models (Fig. 3F). The  
247 complexity scores ranged from 35-205, achieving 15.2-80% accuracy, respectively. A complexity  
248 score of 205 is extremely high and suggestive of overfitting. This ultimately led to highly complex  
249 models with considerable variability (Fig. 3E). Most of the resulting models were linear, with  
250 subsets of models being non-linear for the variables PA-BMD and PA-BMC (Fig. S2)

251           These results are in contrast with the model ensemble using proteomic data, which  
252 demonstrated higher accuracy ( $R^2 = 91.6\%$ ), mean complexity score of 70.3, and much lower  
253 average error rates for single BSI predictions ( $3 \pm 8\%$ ) and for additional BSI predictions ( $8 \pm$   
254  $14\%$ ) across the selected 10 best performing models (Fig. 3D&E, Table S2). The expected ‘knee’  
255 shape is present (Fig. 3B) in the proteomic models, allowing for exploration of a variety of models  
256 with balanced accuracy and complexity. For the proteomic models, the top-5 most frequently  
257 occurring variables across the models included FAAA (100%), OPN (100%), soluble leptin  
258 receptor (LEPR) (90%), Serpin B5 (60%), and trypsin-2 (40%) (Fig. 3F). From the variable  
259 distribution analysis of 2,435 generated models, a frequency of 60-100% in the resultant model  
260 ensemble underscores the predictiveness and consistency of FAAA, OPN, LEPR, and Serpin B5  
261 compared to clinical data, which did not have a single variable represented in more than 50% of  
262 models. Resultant models were primarily linear with non-linear models for OPN and LEPR (Fig.  
263 S3)

264           Combining both clinical and proteomic data yielded the highest accuracy ( $R^2 = 97\%$ ) and  
265 lowest error rates for single BSI predictions ( $3 \pm 8\%$ ) and for additional BSI predictions ( $5 \pm 9\%$ ),  
266 with a modest mean complexity score (63.2) across the selected 11 best performing models (Fig.  
267 3D&E, Table S3). Again, the ‘knee’ shape is present in the model ensembles (Fig. 3C). When  
268 clinical and proteomic data were combined, history of anorexia replaced LEPR as the third most  
269 common frequent variable (67% of models) in the combined ensembles, yet history of anorexia  
270 had not previously been identified in the clinical data models (Fig. 3F). Of note, only two  
271 individuals had a history of anorexia nervosa. For the combined models, the top-5 most frequently  
272 occurring variables across the selected models included FAAA (100%), OPN (100%), history of  
273 anorexia nervosa (72.7%), trypsin-2 (54.5%), red blood cell distribution width (RDW) (27.3%)  
274 (Fig. 3F). Resultant models were primarily linear with non-linear models for FAAA and OPN (Fig.  
275 S4)



276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290


**Figure 3: Genetic programming models were evaluated for accuracy and complexity using clinical, proteomic, and combined datasets.** Models were generated using genetic programming to create candidate models and evaluate complexity and accuracy. The top ten models are highlighted in red and blue circles. (A) Clinical data produced minimal models that were both accurate and complex, noted by the absence of the ‘knee’ configuration in the plot. (B) Proteomic data produced the characteristic ‘knee’ shape, allowing for exploration of features that generate highly accurate and minimally complex models. (E) Model accuracy was compared as well as (F) model complexity, with combined datasets performing best. (D) Variable presence in the model ensembles were compared between clinical, proteomic, and combined datasets. Clinical data lacked variables present in >50% of the generate models. In contrast, proteomic data produced 4 variables present in > 50% of models with FAAA appearing in 100% of models. Combined datasets performed similarly with the inclusion of a history of anorexia as the top feature from the clinical dataset.

291 **Candidate biomarkers have a temporal expression pattern in additional vs. single BSI**  
292 **individuals.**

293 The top protein features from the sPLS-DA and genetic programming models were  
294 analyzed over the one-year follow-up including baseline, 6, 12, 24, and 52 weeks. Exploring  
295 candidate biomarker proteins across sPLS-DA models and genetic programming, we investigated  
296 the temporal patterns of FAAA, trypsin-2, and osteopontin. FAAA levels were higher in  
297 individuals who experienced additional BSIs compared to those with a single BSI at enrollment,  
298 week 6, and week 24 (enrollment,  $p = 0.004$ ; week 6,  $p = 0.03$ ; week 24,  $p = 0.05$ ) (Fig. 4A). By  
299 contrast, Trypsin-2 levels were consistently lower in individuals with additional BSIs compared to  
300 those with a single BSI at all examined timepoints (enrollment,  $p = 0.002$ ; week 6,  $p = 0.02$ ; week  
301 12,  $p = 0.003$ ; week 24,  $p = 0.01$ ; week 52,  $p = 0.003$ ) (Fig. 4B). OPN levels were higher in  
302 individuals with additional BSIs compared to those with a single BSI at enrollment and week 24  
303 (enrollment,  $p = 0.01$ ; week 24,  $p = 0.005$ ) (Fig. 4B). Given that the occurrence of additional BSIs  
304 varied in timing among individuals, we were unable to identify the FAAA, trypsin-2, or OPN  
305 levels that corresponded to the timing of the second or third BSI onset.

306 We further explored the time dependent differences in key features from the sPLS-DA  
307 models, specifically characterizing VEGF sR2, TNF sR-II, and adiponectin (Fig. D-F). VEGF sR2  
308 levels were higher in individuals who experienced additional BSIs compared to those with a single  
309 BSI at enrollment, week 6, and week 24 (enrollment,  $p = 0.01$ ; week 6,  $p = 0.04$ ; week 24,  $p =$   
310  $0.05$ ) (Fig. 4D). By contrast, TNF sRII levels were consistently lower in individuals with additional  
311 BSIs compared to those with a single BSI at all examined timepoints (enrollment,  $p = 0.02$ ; week  
312 6,  $p = 0.01$ ; week 12,  $p = 0.003$ ; week 24,  $p = 0.01$ ; week 52,  $p = 0.0002$ ) (Fig. 4E). Adiponectin  
313 levels were lower in individuals with additional BSIs compared to those with a single BSI at  
314 enrollment and week 24 (enrollment,  $p = 0.004$ ; week 24,  $p = 0.05$ ) (Fig. 4F). Again, the protein  
315 levels were most different between groups at enrollment and at week 24, immediately following 3  
316 additional BSIs events (Table 1). Yet, proteomic expression of FAAA and Trypsin-2 showed  
317 sustained temporal patterns in proteomic levels between single and additional BSI groups (Fig.  
318 4A&B). Notably, week 24 was different for FAAA, trypsin-2 and OPN, which followed 5 of the  
319 additional BSI events and preceded 5 more BSIs (Table 1), suggesting that these proteins may be  
320 elevated following or prior to subsequent BSI.

321




322 **Figure 4: Serum proteins represented in predictive models displayed distinct**  
323 **expression patterns over time between additional and single bone stress injury (BSI)**  
324 **groups.** (A-C) Proteins identified in both sparse partial least squares discriminant analysis  
325 (sPLS-DA) and genetic programming models, such as fumarylacetoacetase (FAAA),  
326 trypsin-2, and osteopontin (OPN), exhibited temporal expression differences. (D-F)  
327 Proteins identified only in the sPLS-DA model, including vascular endothelial growth  
328 factor receptor 2 (VEGF sR2), tumor necrosis factor receptor superfamily member 1B  
329 (TNF sR-II), and adiponectin, also showed significant temporal variation. Data are  
330 presented as mean  $\pm$  SEM ( $n = 10$  for additional BSI,  $n = 20$  for single BSI, analyzed using  
331 linear mixed-effects model (\* $p < 0.05$ , \*\* $p < 0.001$ ).  
332

333 **Additional BSI was associated with early dysregulation in proteins involved in blood clotting**  
334 **and immune function**

335 While proteomic analysis was useful for the biomarker identification and risk  
336 classification, biomarkers alone do not give insights into biological pathways involved in  
337 additional BSI risk. Therefore, functional pathways altered between additional and single BSI  
338 groups were assessed through a gene set enrichment analysis (21). Proteins were first analyzed for  
339 differential expression between groups while blocking for time using the ExpressAnalyst package  
340 (22) based on the *limma* package (23) in R (R 4.4.1). This analysis revealed 112 significantly  
341 different proteins expressed between additional and single BSI individuals [ $\log_2$  FC > 0.5,  
342 Benjamini-Hochberg false discovery rate (FDR) adjusted p-value < 0.05] (Data File S5). Notably,  
343 76 of these genes were found to be upregulated, while 36 were downregulated, indicating  
344 substantial biological divergence that corresponds to subsequent BSIs (Fig. 5A). Of these proteins,  
345 several key proteins identified in sPLS-DA and genetic programming models were also  
346 significantly differentially expressed proteins, including FAAA, trypsin-2, OPN, TNFs RII, VEGF  
347 sR2, LEPR, and adiponectin (Fig. 5A).

348 To enable Gene Set Enrichment Analysis (GSEA) with proteins, the initial panel of 1,500  
349 proteins were mapped to 1,207 corresponding unique genes via EntrezID to enable the analysis  
350 through established gene network databases. Dysregulated pathways were identified in individuals  
351 with an additional BSI as compared to a single BSI. Downregulated pathways in the additional v.  
352 single BSI groups included immune system function, adaptive and innate immunity, interleukin-  
353 10 (IL-10) signaling, neutrophil degranulation, and signaling by interleukins (Fig. 5C).  
354 Significantly upregulated pathways in the additional v. single BSI included formation of fibrin  
355 clot, intrinsic pathway of fibrin clot formation, and hemostasis (Fig. 5C). A full list can be found  
356 in the supplement (Data File S6). Of the significant pathways, six are primarily associated with  
357 the immune system, while the remaining three are linked to blood clotting processes. Formation  
358 of fibrin clot (clotting cascade) (R-HSA-140877) included protein C (PROC), a2-macroglobulin  
359 (A2M), kallikrein B1 (KLKB1), thrombin (F2), and coagulation factor VII (F7) (Fig. 5B). Immune  
360 system (R-HAS-168256) included 24 immune system related proteins, notably trypsin-2 and TNF  
361 sRII, which were present in the sPLS-DA models (Fig. 5B).

362 Because blood clotting pathways were significantly upregulated in additional BSI  
363 individuals, we explored if type of contraceptive (combined oral, progestin-releasing IUD,  
364 previously history of combined oral, or never used) contained any overlap with the protein profile  
365 identified in additional BSI individuals. Hormonal contraceptives may influence blood clotting  
366 pathways (24) as well as bone density and metabolism (25) and may be a confounding factor in  
367 this study. However, our sPLS-DA analysis of protein signatures relating to type of contraceptive  
368 did not contain overlapping proteins with the dysregulated proteins in the additional BSI  
369 individuals (Fig. S4 A&C). We also explored if MRI grade was associated with the dysregulated  
370 proteins in this study but found no overlap in MRI grade proteins and BSI risk proteins (Fig. S4  
371 B&D).



372  
373  
374  
375  
376  
377  
378  
379  
380  
381

**Figure 5: Individuals with additional bone stress injury (BSI) show increased blood clotting and decreased immune system proteins over time.** (A) Volcano plot of differentially expressed serum proteins up- or downregulated in additional BSI v. single BSI individuals. (B) Heatmap of proteins from pathways including “formation of fibrin clot” and “immune system” that were identified in (C) a gene set enrichment analysis of differentially expressed proteins in additional BSI v. single BSI individuals. All data are aggregated per individual over 52 weeks and analyzed, blocking for time, for both the differential expression and gene set enrichment analysis (GSEA) analysis.

## 382 DISCUSSION

383 Pathogenesis of BSIs is both complex and remains poorly understood. Biological and  
384 biomechanical factors contribute to subsequent BSIs, but clear clinical risk indicators are lacking.  
385 This study aimed to identify protein signatures in individuals who experience subsequent BSIs to  
386 address these clinical challenges. We conducted an in-depth proteomic analysis of female athletes  
387 with and without recurrent BSI. Our findings revealed that subsequent BSI risk can be predicted  
388 by early serum proteomic profiles. Using multivariate modeling, a sparse partial least squares  
389 discriminant analysis (sPLS-DA) model identified six candidate biomarkers (FAAA, trypsin-2,  
390 OPN, TNF sR-II, and VEGF sR2) with an accuracy of 91-96% in predicting recurrent BSI risk  
391 category from enrollment proteins alone. Analysis of protein changes over time revealed 112  
392 significantly different proteins, mapped to biological pathways associated with decreased immune  
393 system function and increased blood clotting pathways.

394 Genetic programming further validated the candidate biomarkers, identifying FAAA as a  
395 key predictor of subsequent BSIs. Notably, clinical metrics alone were insufficient to distinguish  
396 between single and recurrent BSI groups. While combining clinical metrics with proteomic data  
397 slightly enhanced genetic programming models, combined data did not outperform proteomic data  
398 in sPLS-DA models, demonstrating the superior predictive power of proteomic information. This  
399 integration of high-resolution proteomic data enabled the application of standard machine learning  
400 methods on a relatively small dataset, surfacing a highly informative feature set far surpassing the  
401 predictive value of standard clinical data. Our study not only provides the most comprehensive  
402 proteomic dataset for BSIs in the underexplored population of female athletes but also identifies  
403 candidate biomarkers for recurrent BSIs, offering valuable insights for targeted therapeutic  
404 interventions and improved clinical prediction strategies.

405 Multivariate linear regression models through sPLS-DA identified FAAA as the marker  
406 (at enrollment, < 3 weeks of initial BSI) that most positively correlated with additional BSI and  
407 Trypsin-2 as the marker (at all time points) most negatively correlated. These proteins have not  
408 been previously identified as biomarkers for BSI risk, and their role in bone health is not well  
409 understood. FAAA has been implicated as a serum biomarker for idiosyncratic drug-induced liver  
410 injury when increased (26, 27) and as a urine biomarker for acute hypercoagulable states in  
411 preclinical models when decreased (28, 29). In drug-induced liver inflammation, FAAA positively  
412 correlates with alanine aminotransferase (ALT) (26). While ALT was not assessed in our clinical  
413 metrics, ALT was measured via our Somamer panel and was found to positively correlate with  
414 FAAA levels (Fig. S5, Adj.  $R^2 = 0.19$ ,  $p < 0.0001$ ), yet no overt liver diseases were reported in  
415 patient medical histories. Alcohol consumption was also not evaluated in this study. Participants  
416 were taking a variety of medications, precluding any clear correlations with potential drug-induced  
417 liver injury. Another consideration is the use of athletic or herbal supplements, which can be  
418 associated with liver injury (30) but are difficult to track due to poor reporting and labeling.  
419 Although we did not adequately assess supplement intake in this study cohort, other studies have  
420 shown that runners with a history of BSI report more frequent supplement intake (31) and athletes  
421 generally take more types of supplements than non-athletes, with elite athletes having the highest  
422 rate of supplement use (32, 33). In the additional BSI group, the proteins FAAA, aldehyde  
423 dehydrogenase 1 family member B1 (ALDH1B1), and cytochrome P450 family 3 subfamily A  
424 member 4 (CYP3A4) were all upregulated together and relate to the functional pathway of  
425 “metabolism” (R-HSA-1430728). Both ALDH1B1 and CYP3A4 are liver enzymes that regulate  
426 drug metabolism (34) and alcohol metabolism (35). Therefore, elevated liver metabolism enzymes



427 such as FAAA, ALDH1B1, and CYP3A4 suggest a potential challenge to the liver that may be  
428 due to supplement use or alcohol intake. Liver health status should be further considered for those  
429 at risk of recurrent BSI.

430 Trypsin-2, also known as PRSS2 or tumor-associated trypsin, has been implicated as a  
431 biomarker in pancreatitis (36), ulcerative colitis (37), and diabetes (38), as well as the progression  
432 of tumor growth by immunosuppression via interaction with myeloid cells (39). Only recently has  
433 trypsin-2 been described in human bone marrow, specifically in the hematopoietic stem cell niche  
434 and highly expressed in early, undifferentiated hematopoietic progenitor cells and mobilized  
435 CD34<sup>+</sup> hematopoietic cells (40). However, understanding of the role of trypsin-2 in the bone  
436 marrow is limited to the maintenance of the stem cell niche by complex diffusion interaction in  
437 the local microenvironments (40), not serum accumulation and potential endocrine signaling  
438 within bone marrow. Here we observed that trypsin-2 levels were the strongest positive correlative  
439 variable in the sPLS-DA models and the fourth most frequent variable in genetic program models  
440 of combined proteomic and clinical data. Trypsin-2 was increased in the single BSI group  
441 compared to the additional BSI group at all time points. Only trypsin-2 and TNF sRII were found  
442 to be different at all timepoints in the additional BSI group. The diminished trypsin-2 in the  
443 additional BSI group corresponds with a reduction in immune pathways, including neutrophil  
444 degranulation and innate immune system function, both of which contain trypsin-2 within the  
445 pathway categories. These data highlight that elevated serum trypsin-2 levels are positively  
446 correlated with successful BSI recovery at early time points and throughout the time course of  
447 healing. Diminished trypsin-2 was accompanied by immunosuppressive pathways, suggesting a  
448 role for diminished innate immune signaling in those with additional BSIs. A limitation of the  
449 interpretation of the absolute levels of trypsin-2 is that this study did not include an uninjured  
450 control group, so we cannot determine how the level of trypsin-2 relates to other health conditions  
451 in which it has been identified as a biomarker.

452 Osteopontin (OPN) was identified as the second most frequent variable in genetic  
453 programming models for both the proteomic and combined models, occurring in 100% of the  
454 models selected in the model ensemble. Yet, OPN was only a modest negative predictor of  
455 additional BSI in the sPLS-DA models. OPN also did not appear in any of the differentially  
456 expressed pathways but was increased in additional BSI individuals at enrollment and at 24 weeks  
457 post injury. OPN was found to be elevated in severe liver dysfunction (41), as well as with severe  
458 inflammatory injury and sepsis (42). Elevated levels of OPN are associated with unfavorable  
459 prognoses, including mortality, in critically ill patients with SARS-CoV-2 (COVID19) (43).  
460 Broadly, OPN is known to have an inflammatory role, and is associated with other pro-  
461 inflammatory cytokines, such as C-reactive protein (CRP) and interleukin-6 (IL-6), all of which  
462 have been shown to increase following bone trauma (44). We also observed in our time course  
463 analysis that OPN peaked in the additional BSI group both at the enrollment visit (within 3 weeks  
464 of BSI diagnosis) and again at week 24. This OPN 24-week peak was after an additional BSI in 5  
465 individuals and preceded an additional BSI in 5 others. The elevated levels of OPN and other  
466 proteins, at both baseline and week 24 (in and around the additional BSI events), strengthens the  
467 evidence that such proteins correspond to injury-related biomarkers. Overall, elevated OPN in the  
468 additional BSI group suggests a chronic inflammatory condition.

469 While immunosuppressive markers are known to correlate to increased fracture risk, this  
470 is primarily understood for comorbidities such as organ transplantation and steroid use (45).  
471 Similar mechanisms in otherwise healthy populations have not been well studied. However,

472 intense exercise and overtraining can cause a diminished immune response (46) and intense  
473 exercise produces a robust inflammatory response (47), highlighting a knowledge gap in the role  
474 of the immune system in bone quality in athletes. Our pathway analysis for proteins up- or down-  
475 regulated with additional BSI risk indicates an impaired or suppressed immune response, which  
476 may delay or complicate the recovery process following an injury. In multiple patient studies  
477 involving traumatic bone injuries, sustained immune suppression has corresponded to impaired  
478 bone healing (48). Of note, IP-10 (also known as C-X-C motif chemokine 10 (CXCL10)), was  
479 decreased in the additional BSI group in our time-independent analysis. We have previously shown  
480 that serum levels of IP-10 correlated with poor bone healing outcomes in preclinical models of  
481 severe muscle and bone trauma with cellular evidence of prolonged immunosuppression (14).

482 We observed biologically upregulated pathways related to fibrin clot formation, the  
483 intrinsic clotting cascade, and hemostasis. Intense exercise is known to induce both coagulation  
484 and fibrinolysis, a process typically balanced under normal conditions (49). In our study, we noted  
485 an increase in thrombin (F2), a key regulator of hemostasis (50). This increase was not associated  
486 with the severity of fractures, as thrombin was not associated with the sPLS-DA for MRI grade  
487 (Fig. S4 B&D). While oral contraceptives are thought to create a clinically prothrombotic state,  
488 affecting both coagulation and fibrinolysis, we found no association between contraceptive use  
489 and blood clotting proteins (Fig. S4 A&C). Elevated proteins within the fibrin clot formation  
490 pathways included intrinsic clotting factors, such as KLKB1 and PROC, and extrinsic clotting  
491 factors, including coagulation F7, F2, and A2M. The pro-coagulation proteins were elevated  
492 alongside inhibitory proteins. Therefore, without functional coagulation assessment, our  
493 conclusions are limited to the elevation of proteins attributed to blood clot formation and  
494 hemostasis pathways. These findings are consistent with other studies of athletes undergoing  
495 intense exercise training (47, 49, 51, 52). In the present study, we did not observe differences in  
496 training level between the single and additional BSI groups (11). Therefore, elevated pro-  
497 coagulatory proteins suggest that the additional BSI group might be more affected by exercise-  
498 related coagulation changes, thereby increasing their risk of subsequent BSIs.

499 Surprisingly, none of the clinical bone morphometric data were determined to be frequent  
500 variables in our combined clinical and proteomic models corresponding to additional BSI risk.  
501 Variables appear more frequently in the model ensembles if the features hold higher influence on  
502 predictive models and provide generalizability to the larger dataset. In the original study, we  
503 observed a decrease in cortical TMD and a decrease in finite element model analysis (FEA)  
504 stiffness from the distal tibia in the additional vs. single BSI groups (11). Tibial cortical TMD  
505 appeared in the sPLS-DA clinical models as well as tibial cortical vBMD, both of which were  
506 acquired using HR-pQCT. Whereas in genetic programming models, the DXA-based lumbar spine  
507 BMC appeared in the clinical model ensemble. Interestingly, in the combined model ensemble,  
508 DXA-based BMC was replaced by RDW, which has previously been negatively correlated to  
509 DXA-based BMD and increased risk of fracture (53, 54). Neither the genetic programming nor  
510 sPLS-DA clinical models were highly predictive for clinical data alone. Tibial length was included  
511 as the most frequent variable in the genetic program models of clinical metrics alone, but frequency  
512 in the models was 40% and comparable to frequency of other top variables, including absolute  
513 lymphocyte count (40%), vitamin D (30%), and age at menses onset (30%). Together, this implies  
514 that the clinical data variable are present in a relatively flat data plane are likely overfitted in our  
515 relatively small dataset. We would expect that if the clinical models were tested on a new dataset,  
516 they may not perform well in stark contrast to the proteomic datasets.

517 When proteomic and clinical data were combined, history of anorexia nervosa emerged as  
518 the third most frequent variable, present in 72.7% of the models, replacing LEPR. This finding  
519 suggests that both a history of anorexia nervosa and LEPR protein levels may be interchangeable  
520 in our models in relation to BSI outcomes. Low leptin levels are consistently noted in those with  
521 low weight anorexia nervosa (55–57). However, given that only five individuals in our study had  
522 a known history of anorexia, a follow up study would be needed to specifically evaluate the role  
523 of anorexia in our recurrent BSI models in a larger sample size. Problematic or prolonged low  
524 energy availability (LEA) from an eating disorder or disordered eating can lead to Relative Energy  
525 Deficiency in Sport (REDs), a syndrome in which bone quality and health are often impaired (58).  
526 LEA is major risk factor for BSI occurrence (59), so our finding of a history of anorexia being a  
527 positive predictor of subsequent BSI is not surprising. While no participants had a known current  
528 eating disorder throughout the study, it is plausible that they still had subclinical disordered eating  
529 or that there are lasting effects of a past anorexia diagnosis on metabolic function or lifestyle.  
530 Therefore, in our study, a history of anorexia may be supplemented in the models to simplify and  
531 improve the accuracy of the genetic programming models by replacing several individual proteins.

532 Our study achieved ~97% accuracy in predicting additional BSIs using sPLS-DA and  
533 genetic programming models with primarily proteomic data and effectively identified candidate  
534 biomarkers in relatively small biological datasets. This highlights how high-resolution proteomic  
535 data can enhance the predictive power of models through the synergistic effects of standard  
536 machine learning models with the appropriate dataset. However, evaluating model performance  
537 solely on error rates may not fully assess effectiveness. Genetic programming suggests that  
538 increased complexity can lead to less generalizable models, making it crucial to examine model  
539 distributions within the ensemble. Ideally, ensembles should exhibit a 'knee' shape in their context  
540 plot, balancing error minimization and complexity. In our study, this 'knee' configuration was  
541 absent in models relying solely on clinical metrics, indicating inefficiencies and potential  
542 overfitting. Conversely, proteomic models showed lower error rates and retained the 'knee' shape.  
543 This demonstrates that integrating detailed biomolecular profiles enhances the robustness and  
544 accuracy of predictive models in clinical applications.

545 Our study has several limitations. While our results identified significant correlations  
546 between specific proteins and recurrent BSIs, establishing causal relationships would require  
547 further investigation. Multivariate models based on high dimensional, low sample size datasets are  
548 common in clinical research but face challenges like possible overfitting and increased complexity,  
549 complicating validation and interpretation. We sought to overcome these limitations by using both  
550 sPLS-DA and genetic programming models to explore both linear and non-linear relationships in  
551 the data as well as independent models with different assumptions. While most features presented  
552 as linear relationships in our datasets, there were subsets of proteomic data that were identified as  
553 non-linear relationships in genetic programming model ensembles, validating that both linear and  
554 non-linear relationships should be explored.

555 Our results were also limited to the demographics of the study group, which includes  
556 relatively healthy, young female athletes with diagnosed BSI as well as a skewed distribution of  
557 individuals. Although our study demonstrated clear clustering between the study groups, we lack  
558 a test population to fully validate the identified candidate biomarkers for subsequent BSIs.  
559 Additionally, we lacked an injury-free control group, which would have aided in understanding  
560 the protein levels regarding health or disease. Nevertheless, our study identified 10 significant  
561 candidate biomarkers that appeared in 80% of the sPLS-DA models, including FAAA,

562 Osteopontin, and Trypsin-2, with a predictive accuracy of  $95 \pm 0.02\%$  validated through leave-  
563 one-out cross-validation. Time-course differential expression analysis highlighted 112  
564 differentially expressed proteins linked to pathways of increased fibrin clot formation and  
565 decreased immune signaling in individuals with additional BSIs. Our data highlight differences  
566 based on subsequent BSI risk in a relatively homogeneous study population (young, female  
567 athletes), adding to the strength of these findings as they relate to additional BSI risk in our study  
568 population.

569 The clinical implications of our study include the identification of (1) candidate biomarkers  
570 of subsequent BSIs in young, female athletes, (2) pathway signatures of immunosuppression and  
571 increased blood clotting with subsequent BSIs, and (3) an innovative approach to identifying and  
572 validating candidate biomarkers in relatively small clinical study populations. Further studies are  
573 required to prospectively validate FAAA, OPN, and Trypsin-2 as biomarkers of subsequent BSIs,  
574 as well as their relationship in a broader study population. Additionally, the relationship between  
575 functional immunosuppression and increased blood clotting should be further explored in athletes  
576 with BSI.

577 In conclusion, this study presents a robust statistical workflow, enhanced by machine  
578 learning, to analyze high-resolution proteomic data, paving the way for advancements in reinjury  
579 risk assessment. Our study underscores a critical gap in sports medicine: clinical metrics alone are  
580 insufficient to predict risk of recurrent BSIs, leading to potential discrepancies in determining  
581 appropriate rehabilitation and return to activity protocols. Our data reveal that specific protein  
582 signatures within three weeks of an initial BSI uniquely identify individuals at risk for subsequent  
583 BSI within 52 weeks. While biomarker discovery in small datasets is challenging, advances in  
584 proteomic technologies and machine learning can help isolate critical proteins that differentiate  
585 those with single BSIs from those at higher risk of additional BSI. Through multi-modeling,  
586 subsampling, and cross-validation, we consistently identified candidate biomarkers, reinforcing  
587 their potential as early indicators of additional BSIs. The network analysis of these proteins offers  
588 deeper insights into the biological mechanisms underlying subsequent BSI risk. These findings not  
589 only enhance our understanding of the pathophysiology of BSIs, but also suggest new avenues for  
590 preventive strategies and personalized medicine in sports, with the potential to reduce the  
591 incidence and impact of recurrent injuries.

592

## 593 MATERIALS AND METHODS

### 594 Study Design

595 The design of the clinical study was previously published (11). In brief, local community  
596 recreational female runners who had been diagnosed with a BSI of MRI Fredericson grade 2-4/4  
597 (9) were enrolled in the study and monitored over 52 weeks. Inclusion criteria included a minimum  
598 of 4 hours/week of self-reported weightbearing exercise during the 6 months prior to injury.  
599 Exclusion criteria included known medical conditions that would affect bone health (e.g., current  
600 eating disorder, hyperparathyroidism, celiac disease). Exclusion also included medications known  
601 to affect bone health (e.g., oral steroids, bisphosphonates, lithium). Enrollment attrition is  
602 summarized in Fig. 1, with loss due to disinterest (2 participants), diagnosis > 3 weeks (2  
603 participants), lack of physical activity (1 participants), and dropped participation (2 participants).  
604 Four participants missed more than 1 visit (Fig. 1). Timepoints include enrollment (within 3 weeks  
605 of BSI diagnosis), 6, 12, 24, and 52 weeks post-enrollment. Participants were monitored for  
606 activity levels, bone density (DXA and HR-pQCT), clinical standard-of-care labs, and  
607 development of additional BSIs. Over the course of the study, 10 participants developed a 2<sup>nd</sup> BSI,  
608 one of whom developed a 3<sup>rd</sup> BSI (Table 1). The remaining 20 participants went on to heal and  
609 return to activity uneventfully. Following this study, we re-analyzed serum from all 30 final  
610 participants to retrospectively determine the proteomic signatures between those with a single vs.  
611 additional BSI. Proteomic data are all newly generated data and all analyses are new, including  
612 those with clinical data that have been previously published (11).

613 To overcome the small clinical sample size, multiple machine learning algorithms were  
614 applied to determine robust proteomic signatures in those with an additional BSI compared to those  
615 with a single BSI. These models included sPLS-DA combined with non-parametric machine  
616 learning models: CatBoost (60), logistic regression (61), and random forest (62). LOOCV was  
617 applied to sPLS-DA models to provide robust sub-sampling of the data during model building to  
618 ensure no single individual was skewing the protein signatures. Finally, protein signatures were  
619 analyzed for key biological pathway signatures to glean insights into the systemic dysregulation  
620 in those with additional BSIs. This study was approved by the institutional review boards of  
621 participating institutions and informed consent was obtained prior to participation.

### 622 Dataset

623 The clinical study was previously published (11) and was restricted to the clinical and HR-  
624 pQCT data. New analyses of the serum proteins were completed and the subsequent bioinformatic  
625 approach combined the prior and new data. The current dataset consisted of 30 individuals, 10 of  
626 whom experienced a new BSI event during the 1 year of follow-up. For each participant, the serum  
627 was analyzed with a custom panel of 1,500 proteins by the SOMAscan (SomaLogic, Boulder, CO,  
628 USA) (Data File S2). Detailed methods for the SOMAscan assay have been previously published  
629 (63). In brief, aptamer-based protein capture is utilized to multiplex the analysis and quantify  
630 protein levels in a microarray-based technology.

631 Initially, raw clinical data from the original study (11) were meticulously reviewed to  
632 discern which metrics were relevant. We excluded some variables, such as types and frequency of  
633 exercise and height, which were deemed extraneous and/or noisy for modeling BSI risk.  
634 Additionally, to maintain consistency across the data, categorical variables, such as contraceptive  
635 use, were standardized as categorical variables. A comprehensive workflow was then created to  
636 preprocess the data and create data structures amenable to machine learning approaches.

## 637 **Proteomic Panel Selection & SomaLogic Assay**

638 Previous literature was initially examined to identify key proteins of interest. This led to  
639 the curation of a list containing 1,500 target proteins, each selected for its association with relevant  
640 physiologic categories from pre-fabricated panels provided by SomaLogic, such as  
641 'Cardiovascular Disease', 'Inflammation and Immune Response', 'Metabolic Disease', and  
642 'Oncology', as well as identified proteins of interest from literature (64–66) (full list in Data File  
643 S2). To efficiently align these proteins with the naming convention used by SomaLogic, a  
644 specialized Python program was developed. This program automatically translates gene names, as  
645 cited in prior research, into UniProt IDs. Consequently, a custom panel featuring these 1,500  
646 relevant proteins was created, providing a focused and comprehensive proteomic assay for our  
647 study.

648 Following custom panel creation, serum samples from clotted blood were supplied to  
649 SomaLogic for aptamer-based analysis. Samples were obtained from 30 individuals from the prior  
650 BSI study (11). SomaLogic assay has been described previously. In brief, samples are analyzed  
651 with custom slow off-rate aptamers designed for up to 7,000 human proteins. Concurrent analysis  
652 of the custom 1,500 protein panel is done from 55 uL of serum and samples are normalized with  
653 SomaLogic's custom and robust internal and plate-to-plate normalization methods (67). Standard  
654 mathematical normalization techniques ( $\log_2$  and mean centering) were applied before further  
655 processing. A subset of samples were flagged (6/145 samples) because the samples failed to  
656 hybridize in the initial step and were re-run successfully. Flagged samples can occur with bubble  
657 formation or other technical difficulties during assay processing.

## 658 **Data Preprocessing**

659 Optimal data preprocessing was identified by comparing the methods: standardization,  
660 variance stabilization normalization (VSN), quantile, linear-regression, and mean-centered  
661 approaches, each of which are widely accepted preprocessing methods. Resulting box-plot  
662 distributions were compared for equitable distribution of the data and standardization emerged as  
663 the most effective normalization technique. Transformation was similarly scrutinized, with  $\log_2$ ,  
664  $\log_{10}$ , and box-cox evaluated. The  $\log_2$  transformation was selected because it stabilized the  
665 variance of high intensities but increased the variance at low intensities, allowing for more uniform  
666 evaluations (68). Standardization and  $\log_2$  transformations were applied to all datasets.

## 667 **Machine Learning Sparse Partial Least Square Discrimination Analysis (sPL-DA)**

668 Clinical and proteomic data were compiled for analysis using custom Python and R scripts  
669 designed for feature reduction and multivariate modeling. Sparse Partial Least Square  
670 Discriminant Analysis (sPLS-DA) was conducted in R (R 4.4.1) using the MetaboAnalystR 4.0  
671 (69) package. Prior to analysis, the data were preprocessed as described above.

672 The sPLS-DA method was utilized to reduce dimensionality while retaining the most  
673 informative features across clinical, proteomic, and combined datasets. Three components were  
674 computed, with each retaining 10 latent variables (LVs), which maximized group separation. An  
675 orthogonal rotation was applied in the component space to align the axis with the largest group  
676 distinction, thereby ensuring that the selected collection of LVs captured the most meaningful  
677 variation in the data. Score plots were evaluated and components with the largest degree of  
678 separation between 'additional BSI' and 'single BSI' were selected for further analysis.

679 To validate the robustness of the sPLS-DA model and minimize undue influence by single  
680 individuals with our relatively low sample size ( $n = 30$ ), a feature stability test was performed.  
681 Here, one individual was randomly removed from the dataset and models were recorded. This was  
682 repeated 10 times. Models were then compared for the most frequently appearing features. Stable  
683 features were identified if present in over 80% of models during the 10 iterations. Only stable  
684 features were input into the final machine learning models.

685 Machine learning models were applied to the stable features including non-parametric  
686 machine learning models: CatBoost (60), logistic regression (61), and random forest (62). These  
687 models were chosen because they do not assume a specific distribution of the data (70), making  
688 them ideal for complex clinical and proteomic dataset. Feature selection was performed for each  
689 model with subsequent LOOCV, ensuring the most consistent and reliable features were evaluated.  
690 This cross-validation approach provided a rigorous evaluation of the model's predictive capability,  
691 addressing the challenges posed by our dataset's high dimensionality and limited sample size.  
692 Model performance was evaluated by ROC curves, accuracy, sensitivity, and specificity across the  
693 models.

#### 694 **Nonlinear Multivariate Modeling with Genetic Programming**

695 Multivariate, linear and nonlinear regression models were generated using Evolved  
696 Analytics DataModeler software (Version 9.7) in the SymbolicRegression package. Our modeled  
697 outcome was binary as “additional BSI” or “single BSI”. Preprocessed data were uploaded as  
698 “clinical”, “proteomic”, or “combined” (clinical + proteomic) datasets. Total models generated  
699 were 3,020 models for “clinical”, 2,435 models for “proteomic”, and 3,225 models for  
700 “combined”, each over 3 rounds of independent modeling at ten iterations each resulting in 30  
701 total rounds of modeling. Models were then filtered to the “fittest” models, which represent ~50%  
702 of models that satisfied  $< 80$  complexity score and  $< 0.2$  square error rate within the “knee” of the  
703 Pareto front. This reduced models to 65 for “clinical”, 130 for “proteomic” and 258 for “combined”  
704 models. Model ensembles were generated and analyzed using the VariablePresence and  
705 CreateModelEnsemble functions, which represented the diversity of the filtered models for both  
706 complexity and square error rate. Model ensemble statistics are presented in the paper for the 10-  
707 model ensemble for “clinical”, 10-model ensemble for “proteomic”, and 11-model ensemble for  
708 “combined”.

#### 709 **Differential Expression Analysis and Gene Set Enrichment Analysis**

710 ExpressAnalyst package (22) based on the *limma* package (23) in R (R 4.4.1) was utilized  
711 for the differential expression analysis (DEA). Data was  $\log_2$  transformed and mean-centered.  
712 Cutoff criteria included a fold change (FC)  $> 0.5$ . A Benjamini-Hochberg false discovery rate  
713 (FDR) adjusted p-value  $< 0.05$  was applied. Full data can be found in Data File S5. Time was used  
714 as a blocking factor for the differential expression analysis. Gene Set Enrichment Analysis (GSEA)  
715 was used to map the statistical likelihood that sets of identified proteins relate to biological  
716 pathways based on the assumption that the measured proteins would map to gene databases of  
717 known interaction networks. This approach was used because protein interaction networks are less  
718 well developed for high-resolution proteomics and is common for this data type (71). An FDR  $\leq$   
719  $0.05$  and  $p < 0.05$  was also used for the GSEA. A heatmap of the average protein values, z-scored  
720 across timepoints, was used to display the proteins corresponding to the top up- and down-  
721 regulated biological pathways.

722

723 **Statistical Analysis**

724 Data are reported as mean  $\pm$  SEM for time-course analysis of individual proteins. Statistical  
725 analysis was performed for time-dependent variation using a linear mixed effect model, *lme4*  
726 package (72), in R (R 4.4.1) for time series analysis of select proteins with a Tukey’s post-hoc  
727 analysis for contrast results of “additional BSI” v. “single BSI”, specifically for key proteins in the  
728 sPLS-DA and genetic programming models. Statistical significance was determined at  $p < 0.05$   
729 and  $FDR \leq 0.05$  for all components of the study. sPLS-DA and Model ensemble information are  
730 presented in the respective sections above.

731

732 **List of Supplementary Materials**

733 Figures S1-S5

734 Tables S1-S3

735 Data Files S1-S9



## 736 **References and Notes**

- 737 1. L. Wentz, P.-Y. Liu, E. Haymes, J. Z. Ilich, Females Have a Greater Incidence of Stress Fractures Than Males in  
738 Both Military and Athletic Populations: A Systemic Review. *Military Medicine* **176**, 420–430 (2011).
- 739 2. A. S. Tenforde, L. C. Sayres, M. L. McCurdy, K. L. Sainani, M. Fredericson, Identifying sex-specific risk factors  
740 for stress fractures in adolescent runners. *Medicine & Science in Sports & Exercise* **45**, 1843–1851 (2013).
- 741 3. B. R. Waterman, B. Gun, J. O. Bader, J. D. Orr, P. J. Belmont Jr., Epidemiology of Lower Extremity Stress  
742 Fractures in the United States Military. *Military Medicine* **181**, 1308–1313 (2016).
- 743 4. J. R. Kardouni, C. J. McKinnon, K. M. Taylor, J. M. Hughes, Timing of Stress Fractures in Soldiers During the  
744 First 6 Career Months: A Retrospective Cohort Study. *J Athl Train* **56**, 1278–1284 (2021).
- 745 5. M. L. Crunkhorn, L. A. Toohey, P. Charlton, M. Drew, K. Watson, N. Etxebarria, Injury incidence and  
746 prevalence in elite short-course triathletes: a 4-year prospective study. *Br J Sports Med* **58**, 470–476 (2024).
- 747 6. K. L. Bennell, S. A. Malcolm, S. A. Thomas, S. J. Reid, P. D. Brukner, P. R. Ebeling, J. D. Wark, Risk Factors  
748 for Stress Fractures in Track and Field Athletes: A Twelve-Month Prospective Study. *Am J Sports Med* **24**, 810–818  
749 (1996).
- 750 7. J. Sharma, J. P. Greeves, M. Byers, A. N. Bennett, I. R. Spears, Musculoskeletal injuries in British Army recruits:  
751 a prospective study of diagnosis-specific incidence and rehabilitation times. *BMC Musculoskelet Disord* **16**, 106  
752 (2015).
- 753 8. J. P. Greeves, B. Beck, B. C. Nindl, T. J. O’Leary, Current risks factors and emerging biomarkers for bone stress  
754 injuries in military personnel. *Journal of Science and Medicine in Sport* **26**, S14–S21 (2023).
- 755 9. A. Nattiv, G. Kennedy, M. T. Barrack, A. Abdelkerim, M. A. Goolsby, J. C. Arends, L. L. Seeger, Correlation of  
756 MRI grading of bone stress injuries with clinical risk factors and return to play: a 5-year prospective study in  
757 collegiate track and field athletes. *Am J Sports Med* **41**, 1930–1941 (2013).
- 758 10. T. Hoenig, K. E. Ackerman, B. R. Beck, M. L. Bouxsein, D. B. Burr, K. Hollander, K. L. Popp, T. Rolvien, A.  
759 S. Tenforde, S. J. Warden, Bone stress injuries. *Nat Rev Dis Primers* **8**, 1–20 (2022).
- 760 11. K. L. Popp, K. E. Ackerman, S. E. Rudolph, F. Johannesdottir, M. A. Hughes, C. Xu, G. Unnikrishnan, J.  
761 Reifman, M. L. Bouxsein, Changes in Volumetric Bone Mineral Density Over 12 Months After a Tibial Bone Stress  
762 Injury Diagnosis: Implications for Return to Sports and Military Duty. *The American Journal of Sports Medicine* **49**,  
763 226–235 (2021).
- 764 12. K. H. Rizzone, K. E. Ackerman, K. G. Roos, T. P. Dompier, Z. Y. Kerr, The Epidemiology of Stress Fractures in  
765 Collegiate Student-Athletes, 2004–2005 Through 2013–2014 Academic Years. *Journal of Athletic Training* **52**,  
766 966–975 (2017).
- 767 13. M. Fredericson, A. G. Bergman, K. L. Hoffman, M. S. Dillingham, Tibial stress reaction in runners. Correlation  
768 of clinical symptoms and scintigraphy with a new magnetic resonance imaging grading system. *Am J Sports Med* **23**,  
769 472–481 (1995).
- 770 14. A. Cheng, C. E. Vantucci, L. Krishnan, M. A. Ruehle, T. Kotanchek, L. B. Wood, K. Roy, R. E. Guldborg, Early  
771 systemic immune biomarkers predict bone regeneration after trauma. *Proc Natl Acad Sci USA* **118**, e2017889118  
772 (2021).
- 773 15. L. Gold, D. Ayers, J. Bertino, C. Bock, A. Bock, E. Brody, J. Carter, V. Cunningham, A. Dalby, B. Eaton, T.  
774 Fitzwater, D. Flather, A. Forbes, T. Foreman, C. Fowler, B. Gawande, M. Goss, M. Gunn, S. Gupta, D. Halladay, J.  
775 Heil, J. Heilig, B. Hicke, G. Husar, N. Janjic, T. Jarvis, S. Jennings, E. Katilius, T. Keeney, N. Kim, T. Kaske, T.  
776 Koch, S. Kraemer, L. Kroiss, N. Le, D. Levine, W. Lindsey, B. Lollo, W. Mayfield, M. Mehan, R. Mehler, M.

- 777 Nelson, S. Nelson, D. Nieuwlandt, M. Nikrad, U. Ochsner, R. Ostroff, M. Otis, T. Parker, S. Pietrasiewicz, D.  
778 Resnicow, J. Rohloff, G. Sanders, S. Sattin, D. Schneider, B. Singer, M. Stanton, A. Sterkel, A. Stewart, S.  
779 Stratford, J. Vaught, M. Vrkljan, J. Walker, M. Watrobka, S. Waugh, A. Weiss, S. Wilcox, A. Wolfson, S. Wolk, C.  
780 Zhang, D. Zichi, Aptamer-based multiplexed proteomic technology for biomarker discovery. *Nat Prec*, 1–1 (2010).
- 781 16. B. B. Sun, J. C. Maranville, J. E. Peters, D. Stacey, J. R. Staley, J. Blackshaw, S. Burgess, T. Jiang, E. Paige, P.  
782 Surendran, C. Oliver-Williams, M. A. Kamat, B. P. Prins, S. K. Wilcox, E. S. Zimmerman, A. Chi, N. Bansal, S. L.  
783 Spain, A. M. Wood, N. W. Morrell, J. R. Bradley, N. Janjic, D. J. Roberts, W. H. Ouwehand, J. A. Todd, N.  
784 Soranzo, K. Suhre, D. S. Paul, C. S. Fox, R. M. Plenge, J. Danesh, H. Runz, A. S. Butterworth, Genomic atlas of the  
785 human plasma proteome. *Nature* **558**, 73–79 (2018).
- 786 17. J. C. Rohloff, A. D. Gelinas, T. C. Jarvis, U. A. Ochsner, D. J. Schneider, L. Gold, N. Janjic, Nucleic Acid  
787 Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.  
788 *Molecular Therapy - Nucleic Acids* **3** (2014), doi:10.1038/mtna.2014.49.
- 789 18. V. Berisha, C. Krantsevich, P. R. Hahn, S. Hahn, G. Dasarathy, P. Turaga, J. Liss, Digital medicine and the  
790 curse of dimensionality. *npj Digit. Med.* **4**, 1–8 (2021).
- 791 19. R. Raghuraj K., S. Lakshminarayanan, K. Tun, in *2007 IEEE Congress on Evolutionary Computation*, (2007),  
792 pp. 4154–4161.
- 793 20. M. Kotanchev, T. Kotanchev, K. Kotanchev, in *Genetic Programming Theory and Practice XIX*, L. Trujillo, S.  
794 M. Winkler, S. Silva, W. Banzhaf, Eds. (Springer Nature, Singapore, 2023), pp. 91–116.
- 795 21. J. Wang, D. Duncan, Z. Shi, B. Zhang, WEB-based GENE SeT AnaLysis Toolkit (WebGestalt): update 2013.  
796 *Nucleic Acids Research* **41**, W77–W83 (2013).
- 797 22. P. Liu, J. Ewald, Z. Pang, E. Legrand, Y. S. Jeon, J. Sangiovanni, O. Hacariz, G. Zhou, J. A. Head, N. Basu, J.  
798 Xia, ExpressAnalyst: A unified platform for RNA-sequencing analysis in non-model species. *Nat Commun* **14**, 2995  
799 (2023).
- 800 23. M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, G. K. Smyth, limma powers differential  
801 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
- 802 24. J. Douxfils, C. Klipping, I. Duijkers, V. Kinet, M. Mawet, C. Maillard, M. Jost, J. Rosing, J.-M. Foidart,  
803 Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.  
804 *Contraception* **102**, 396–402 (2020).
- 805 25. C. V. Coombs, T. J. O’Leary, J. C. Y. Tang, W. D. Fraser, J. P. Greeves, Hormonal contraceptive use, bone  
806 density and biochemical markers of bone metabolism in British Army recruits. *BMJ Mil Health* **169**, 9–16 (2023).
- 807 26. K. C. Ravindra, V. S. Vaidya, Z. Wang, J. D. Federspiel, R. Virgen-Slane, R. A. Everley, J. I. Grove, C.  
808 Stephens, M. F. Ocana, M. Robles-Díaz, M. Isabel Lucena, R. J. Andrade, E. Atallah, A. L. Gerbes, S. Weber, H.  
809 Cortez-Pinto, A. J. Fowell, H. Hussaini, E. S. Bjornsson, J. Patel, G. Stirnimann, S. Verma, A. M. Elsharkawy, W. J.  
810 H. Griffiths, C. Hyde, J. W. Dear, G. P. Aithal, S. K. Ramaiah, Tandem mass tag-based quantitative proteomic  
811 profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. *Nat Commun* **14**, 1215  
812 (2023).
- 813 27. L. N. Bell, R. Vuppalanchi, P. B. Watkins, H. L. Bonkovsky, J. Serrano, R. J. Fontana, M. Wang, J. Rochon, N.  
814 Chalasani, Serum proteomic profiling in patients with drug-induced liver injury. *Alimentary Pharmacology &*  
815 *Therapeutics* **35**, 600–612 (2012).
- 816 28. J. Jing, Z. Du, Z. Wen, B. Jiang, B. He, Dynamic changes of urinary proteins in a rat model of acute  
817 hypercoagulable state induced by tranexamic acid. *J Cell Physiol* **234**, 10809–10818 (2019).

- 818 29. J. Jing, Z. Du, S. Ji, K. Han, Urinary proteome analysis of acute hypercoagulable state in rat model induced by  $\epsilon$ -  
819 aminocaproic acid. *Biomedicine & Pharmacotherapy* **110**, 275–284 (2019).
- 820 30. V. J. Navarro, I. Khan, E. Björnsson, L. B. Seeff, J. Serrano, J. H. Hoofnagle, Liver injury from herbal and  
821 dietary supplements. *Hepatology* **65**, 363–373 (2017).
- 822 31. M. Barrack, M. Fredericson, F. Dizon, A. Tenforde, B. Kim, E. Kraus, A. Kussman, S. Singh, A. Nattiv, Dietary  
823 Supplement Use According to Sex and Triad Risk Factors in Collegiate Endurance Runners. *The Journal of Strength  
824 & Conditioning Research* **35**, 404 (2021).
- 825 32. J. J. Knapik, R. A. Steelman, S. S. Hoedebecke, K. G. Austin, E. K. Farina, H. R. Lieberman, Prevalence of  
826 Dietary Supplement Use by Athletes: Systematic Review and Meta-Analysis. *Sports Med* **46**, 103–123 (2016).
- 827 33. J. Sundgot-Borgen, B. Berglund, M. K. Torstveit, Nutritional supplements in Norwegian elite athletes—impact  
828 of international ranking and advisors. *Scandinavian Journal of Medicine & Science in Sports* **13**, 138–144 (2003).
- 829 34. G. K. Dresser, J. D. Spence, D. G. Bailey, Pharmacokinetic-Pharmacodynamic Consequences and Clinical  
830 Relevance of Cytochrome P450 3A4 Inhibition. *Clin Pharmacokinet* **38**, 41–57 (2000).
- 831 35. M. J. Way, M. A. Ali, A. McQuillin, M. Y. Morgan, Genetic variants in ALDH1B1 and alcohol dependence risk  
832 in a British and Irish population: A bioinformatic and genetic study. *PLoS One* **12**, e0177009 (2017).
- 833 36. O. Itkonen, E. Koivunen, M. Hurme, H. Alfthan, T. Schröder, U.-H. Stenman, Time-resolved  
834 immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in  
835 pancreatitis. *The Journal of Laboratory and Clinical Medicine* **115**, 712–718 (1990).
- 836 37. W. Wang, L. Wu, X. Wu, K. Li, T. Li, B. Xu, W. Liu, Combined analysis of serum SAP and PRSS2 for the  
837 differential diagnosis of CD and UC. *Clinica Chimica Acta* **514**, 8–14 (2021).
- 838 38. G. H. Eldjarn, E. Ferkingstad, S. H. Lund, H. Helgason, O. T. Magnusson, K. Gunnarsdottir, T. A. Olafsdottir,  
839 B. V. Halldorsson, P. I. Olason, F. Zink, S. A. Gudjonsson, G. Sveinbjornsson, M. I. Magnusson, A. Helgason, A.  
840 Oddsson, G. H. Halldorsson, M. K. Magnusson, S. Saevarsdottir, T. Eiriksdottir, G. Masson, H. Stefansson, I.  
841 Jonsdottir, H. Holm, T. Rafnar, P. Melsted, J. Saemundsdottir, G. L. Norddahl, G. Thorleifsson, M. O. Ulfarsson, D.  
842 F. Gudbjartsson, U. Thorsteinsdottir, P. Sulem, K. Stefansson, Large-scale plasma proteomics comparisons through  
843 genetics and disease associations. *Nature* **622**, 348–358 (2023).
- 844 39. L. Sui, S. Wang, D. Ganguly, T. P. El Rayes, C. Askeland, A. Børretzen, D. Sim, O. J. Halvorsen, G. Knutsvik,  
845 J. Arnes, S. Aziz, S. Haukaas, W. D. Foulkes, D. R. Bielenberg, A. Ziemys, V. Mittal, R. A. Brekken, L. A. Akslen,  
846 R. S. Watnick, PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and  
847 progression. *Nat Commun* **13**, 7959 (2022).
- 848 40. V. Barresi, V. D. Bella, L. L. Nigro, A. P. Privitera, P. Bonaccorso, C. Scuderi, D. F. Condorelli, Temporary  
849 serine protease inhibition and the role of SPINK2 in human bone marrow. *iScience* **26** (2023),  
850 doi:10.1016/j.isci.2023.106949.
- 851 41. M. Arai, O. Yokosuka, T. Kanda, K. Fukai, F. Imazeki, M. Muramatsu, N. Seki, M. Miyazaki, T. Ochiai, H.  
852 Hirasawa, H. Saisho, Serum osteopontin levels in patients with acute liver dysfunction. *Scandinavian Journal of  
853 Gastroenterology* **41**, 102–110 (2006).
- 854 42. R. Vaschetto, S. Nicola, C. Olivieri, E. Boggio, F. Piccolella, R. Mesturini, F. Damnotti, D. Colombo, P.  
855 Navalesi, F. Della Corte, U. Dianzani, A. Chiochetti, Serum levels of osteopontin are increased in SIRS and sepsis.  
856 *Intensive Care Med* **34**, 2176–2184 (2008).

- 857 43. C. Roderburg, F. Benz, D. V. Cardenas, M. Lutz, H.-J. Hippe, T. Luedde, C. Trautwein, N. Frey, A. Koch, F.  
858 Tacke, M. Luedde, Persistently elevated osteopontin serum levels predict mortality in critically ill patients. *Crit*  
859 *Care* **19**, 271 (2015).
- 860 44. J. Cassuto, A. Folestad, J. Göthlin, H. Malchau, J. Kärrholm, The key role of proinflammatory cytokines, matrix  
861 proteins, RANKL/OPG and Wnt/ $\beta$ -catenin in bone healing of hip arthroplasty patients. *Bone* **107**, 66–77 (2018).
- 862 45. S. Kuppachi, W. Cheungpasitporn, R. Li, Y. Caliskan, M. A. Schnitzler, M. McAdams-DeMarco, J. B. Ahn, S.  
863 Bae, G. P. Hess, D. L. Segev, K. L. Lentine, D. A. Axelrod, Kidney Transplantation, Immunosuppression and the  
864 Risk of Fracture: Clinical and Economic Implications. *Kidney Medicine* **4**, 100474 (2022).
- 865 46. L. T. Mackinnon, Chronic exercise training effects on immune function. *Med Sci Sports Exerc* **32**, S369-376  
866 (2000).
- 867 47. E. Balfoussia, K. Skenderi, M. Tsironi, A. K. Anagnostopoulos, N. Parthimos, K. Vougas, I. Papassotiriou, G.  
868 Th. Tsangaris, G. P. Chrousos, A proteomic study of plasma protein changes under extreme physical stress. *Journal*  
869 *of Proteomics* **98**, 1–14 (2014).
- 870 48. A. R. Evans, P. V. Giannoudis, P. Leucht, T. O. McKinley, G. E. Gaski, K. P. Frey, J. C. Wenke, C. Lee, The  
871 local and systemic effects of immune function on fracture healing. *OTA Int* **7**, e328 (2024).
- 872 49. W. Schobersberger, B. Wirleitner, B. Puschendorf, A. Koller, B. Villiger, W. Frey, J. Mair, Influence of an  
873 ultramarathon race at moderate altitude on coagulation and fibrinolysis. *Fibrinolysis* **10**, 37–42 (1996).
- 874 50. J. J. N. Posma, J. J. Posthuma, H. M. H. Spronk, Coagulation and non-coagulation effects of thrombin. *Journal*  
875 *of Thrombosis and Haemostasis* **14**, 1908–1916 (2016).
- 876 51. D. Prisco, R. Paniccia, V. Guarnaccia, G. Olivo, T. Taddei, M. Boddi, G. F. Gensini, Thrombin generation after  
877 physical exercise. *Thromb Res* **69**, 159–164 (1993).
- 878 52. T. Herren, P. Bartsch, A. Haeberli, P. W. Straub, Increased thrombin-antithrombin III complexes after 1 h of  
879 physical exercise. *Journal of Applied Physiology* **73**, 2499–2504 (1992).
- 880 53. K. M. Kim, L.-Y. Lui, J. A. Cauley, K. E. Ensrud, E. S. Orwoll, J. T. Schousboe, S. R. Cummings, Osteoporotic  
881 Fractures in Men (MrOS) Study Research Group, Red Cell Distribution Width Is a Risk Factor for Hip Fracture in  
882 Elderly Men Without Anemia. *J Bone Miner Res* **35**, 869–874 (2020).
- 883 54. Z. Qi, L. Zhang, Z. Li, H. Yu, Q. Li, L. Ma, Y. Yang, Red cell distribution width: a potential marker of reduced  
884 femoral neck bone mineral density in men and postmenopausal women. *Endocrine* (2024), doi:10.1007/s12020-024-  
885 04093-8.
- 886 55. M. Föcker, N. Timmesfeld, S. Scherag, K. Bühren, M. Langkamp, A. Dempfle, E. M. Sheridan, M. de Zwaan,  
887 C. Fleischhaker, W. Herzog, K. Egberts, S. Zipfel, B. Herpertz-Dahlmann, J. Hebebrand, Screening for anorexia  
888 nervosa via measurement of serum leptin levels. *J Neural Transm* **118**, 571–578 (2011).
- 889 56. J. Hebebrand, W. F. Blum, N. Barth, H. Coners, P. Englaro, A. Juul, A. Ziegler, A. Warnke, W. Rascher, H.  
890 Remschmidt, Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-  
891 term weight restoration. *Mol Psychiatry* **2**, 330–334 (1997).
- 892 57. W. Köpp, W. F. Blum, S. von Prittwitz, A. Ziegler, H. Lübbert, G. Emons, W. Herzog, S. Herpertz, H. C. Deter,  
893 H. Remschmidt, J. Hebebrand, Low leptin levels predict amenorrhea in underweight and eating disordered females.  
894 *Mol Psychiatry* **2**, 335–340 (1997).
- 895 58. M. Mountjoy, K. E. Ackerman, D. M. Bailey, L. M. Burke, N. Constantini, A. C. Hackney, I. A. Heikura, A.  
896 Melin, A. M. Pensgaard, T. Stellingwerff, J. K. Sundgot-Borgen, M. K. Torstveit, A. U. Jacobsen, E. Verhagen, R.

- 897 Budgett, L. Engebretsen, U. Erdener, 2023 International Olympic Committee’s (IOC) consensus statement on  
898 Relative Energy Deficiency in Sport (REDs). *Br J Sports Med* **57**, 1073–1097 (2023).
- 899 59. M. T. Barrack, J. C. Gibbs, M. J. De Souza, N. I. Williams, J. F. Nichols, M. J. Rauh, A. Nattiv, Higher  
900 Incidence of Bone Stress Injuries With Increasing Female Athlete Triad–Related Risk Factors: A Prospective  
901 Multisite Study of Exercising Girls and Women. *Am J Sports Med* **42**, 949–958 (2014).
- 902 60. L. Prokhorenkova, G. Gusev, A. Vorobev, A. V. Dorogush, A. Gulin, in *Advances in Neural Information*  
903 *Processing Systems*, (Curran Associates, Inc., 2018), vol. 31.
- 904 61. T. G. Nick, K. M. Campbell, *Logistic Regression* (Humana Press, 2007; DOI [https://doi.org/10.1007/978-1-59745-530-5\\_14](https://doi.org/10.1007/978-1-59745-530-5_14)).
- 906 62. Y. Qi, in *Ensemble Machine Learning: Methods and Applications*, C. Zhang, Y. Ma, Eds. (Springer, New York,  
907 NY, 2012), pp. 307–323.
- 908 63. S. A. Williams, M. Kivimaki, C. Langenberg, A. D. Hingorani, J. P. Casas, C. Bouchard, C. Jonasson, M. A.  
909 Sarzynski, M. J. Shipley, L. Alexander, J. Ash, T. Bauer, J. Chadwick, G. Datta, R. K. DeLisle, Y. Hagar, M.  
910 Hinterberg, R. Ostroff, S. Weiss, P. Ganz, N. J. Wareham, Plasma protein patterns as comprehensive indicators of  
911 health. *Nat Med* **25**, 1851–1857 (2019).
- 912 64. Z. Wang, L. Bian, C. Mo, H. Shen, L. J. Zhao, K.-J. Su, M. Kukula, J. T. Lee, D. W. Armstrong, R. Recker, J.  
913 Lappe, L. F. Bonewald, H.-W. Deng, M. Brotto, Quantification of aminobutyric acids and their clinical applications  
914 as biomarkers for osteoporosis. *Commun Biol* **3**, 1–14 (2020).
- 915 65. A. Moen, A.-L. Lind, M. Thulin, M. Kamali-Moghaddam, C. Røe, J. Gjerstad, T. Gordh, Inflammatory Serum  
916 Protein Profiling of Patients with Lumbar Radicular Pain One Year after Disc Herniation. *International Journal of*  
917 *Inflammation* **2016**, e3874964 (2016).
- 918 66. A. Gurinovich, Z. Song, W. Zhang, A. Federico, S. Monti, S. L. Andersen, L. L. Jennings, D. J. Glass, N.  
919 Barzilai, S. Millman, T. T. Perls, P. Sebastiani, Effect of longevity genetic variants on the molecular aging rate.  
920 *Geroscience* **43**, 1237–1251 (2021).
- 921 67. L. Gold, J. J. Walker, S. K. Wilcox, S. Williams, Advances in human proteomics at high scale with the  
922 SOMAscan proteomics platform. *New Biotechnology* **29**, 543–549 (2012).
- 923 68. J. Ambroise, B. Bearzatto, A. Robert, B. Govaerts, B. Macq, J.-L. Gala, Impact of the spotted microarray  
924 preprocessing method on fold-change compression and variance stability. *BMC Bioinformatics* **12**, 413 (2011).
- 925 69. Z. Pang, L. Xu, C. Viau, Y. Lu, R. Salavati, N. Basu, J. Xia, MetaboAnalystR 4.0: a unified LC-MS workflow  
926 for global metabolomics. *Nature Communications* **15**, 3675 (2024).
- 927 70. S. Siegel, Nonparametric Statistics. *The American Statistician* **125**, 497 (1957).
- 928 71. P. Sivakumar, M. Saul, D. Robinson, L. E. King, N. B. Amin, SomaLogic proteomics reveals new biomarkers  
929 and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic  
930 Steatohepatitis (NASH). *Sci Rep* **14**, 17072 (2024).
- 931 72. H. Doran, D. Bates, P. Bliese, M. Dowling, Estimating the Multilevel Rasch Model: With the lme4 Package.  
932 *Journal of Statistical Software* **20**, 1–18 (2007).
- 933
- 934

935 **Acknowledgments:** We would like to acknowledge the clinical research team at Boston  
936 Children’s Hospital for efforts in patient recruitment, data collection, and management.  
937 We would also like to thank Dr. Mark Kotancheck for assistance with the DataModeler  
938 software, Dr. Dan Lowd for assistance with machine learning models, Dr. Clay Small and  
939 Dr. Karl Romanowicz for bioinformatic discussions, as well as Dr. Bill Cresko for  
940 reviewing the biostatistics, machine learning, and manuscript prior to submission. The  
941 opinions or assertions contained herein are the private views of the author(s) and are not  
942 to be construed as official or as reflecting the views of the Army, the Department of  
943 Defense, National Institute of Health, or the U.S. Government.

944 The opinions or assertions contained herein are the private views of the authors and are  
945 not to be construed as official or reflecting the views of the U.S. Army or the Department  
946 of Defense. Any citations of commercial organizations and trade names in this report do  
947 not constitute an official U.S. Army, Department of Defense endorsement or approval of  
948 the products or services of these organizations. This paper has been approved for public  
949 release with unlimited distribution.

950 Artificial intelligence (AI) assisted technologies (ChatGPT-4, GitHub Copilot leveraging  
951 ChatGPT4o) were used to aid in code revision and debugging as well as revision of text  
952 used in the manuscript. All code was evaluated and checked to ensure accuracy and is  
953 available on GitHub. Throughout the manuscript, text was reviewed after prompts such as  
954 “revise” and “condense” were used to aid in clarification of the text and reducing word  
955 count. The authors take full responsibility for both the coding and written content of this  
956 manuscript.

957 **Funding:**  
958 United States Department of Defense, Defense Health Program, and Joint Program  
959 Committee (W811XWH-15-C-0024) (PI: Bouxsein ML);  
960 Wu Tsai Human Performance Alliance (Multi-PIs: Ackerman KE, Guldborg RE);  
961 NIH-NIDCR, K99DE033689 (PI: Romanowicz GE);  
962 Knight Campus Undergraduate Scholarship (Dinh)

963 **Author contributions:**  
964 Conceptualization: GER, KP, ED, IH, KL, KEA, MLB, REG  
965 Methodology: GER, KP, ED, IH, KL, REG  
966 Investigation: GER, KP, ED, IH, JMH, KEA  
967 Visualization: GER, ED, IH  
968 Funding acquisition: GER, MLB, KEA, REG  
969 Project administration: GER, KP, MLB, REG  
970 Supervision: GER, KP, MLB, REG  
971 Writing – original draft: GER, ED  
972 Writing – review & editing: GER, KP, ED, IH, KL, JMH, KEA, MLB, REG

973 **Competing interests:** Authors declare that they have no competing interests.

974 **Data and materials availability:**

975 All data are available in the main text or the supplementary materials. Code relating to  
976 the analysis is available on GitHub: <https://github.com/GuldborgLab/BSI-Study-2024>

977